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WT KRASAbstract KRAS mutation is widely accepted as a key factor in colorectal tumorigenesis. Although
KRAS mutation is widely studied in CRC limited data are available about mutation rates and spec-
trum in CRC from developing countries like Saudi Arabia where epidemiological features of the
disease are different. We studied retrospectively tumor samples of 83 Saudi metastatic CRC patients
for KRAS mutations in codon 12 and codon 13, to evaluate the relevance of KRAS mutation posi-
tive colorectal cancers with metastatic sites. KRAS mutation was observed in 42.2% (35/83)
patients with CRC. The most common mutations were in codon 12 (p.G12D, 46%; 16/35,
P< 0.0001), codon 12 (pG12V, 31%; 11/35, P< 0.0001), and codon 13 (p.G13D, 11%; 4/35,
P< 0.016). Of these 51% and 23% of the tumors are from the left hemicolon and rectum respec-
tively, 83% were moderately differentiated and 86% were invasive adenocarcinoma. Observed
mutations are 74% in patients with advanced stage CRC (P= 0.006). Among patients with KRAS
mutated CRC (CRC) isolated lung and liver metastases were 32% and 23% whereas in WT KRAS
was 3% and 53.1% (P< 0.005) respectively. The study revealed 69% and 81% of colorectal
patients that responded to treatment with complete response (CR)/partial response (PR)/stable dis-
ease (SD) were KRAS mutated and WT KRAS respectively (P= 0.182). In the mutated KRAS
cohort 31% had disease progression compared to 19% in WT KRAS (P= 0.182). Multivariate
logistic regression analysis showed WT CRC associated with 3-fold increase in positive response
to ﬁrst-line treatment with an odds ratio of 2.83; 95% CI 0.910–8.832. The frequency of KRAS1; CR,
sphate;
mCRC,
serine/
andria,
204 T. Bader, A. Ismailmutations appears higher in the Saudi population. KRAS mutated CRC patients had a higher pro-
pensity for lung metastases by passing liver metastases indicating the need for more extensive chest
imaging for effective staging. KRAS WT responds better to treatment compared to KRAS mutated
colorectal cancers.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Colorectal cancer (CRC) is the second most common cancer in
developed countries, only surpassed by prostate cancer in men
and breast cancer in women, and accounts for about 1 million
new cases in 2002 and 530,000 deaths every year.1 In Saudi
Arabia it is the commonest cancer among males (11.8%) and
third among females (8.8%) superseded only by breast and
thyroid cancers.2 Surgery is still the only curative treatment
for patients with colorectal cancer, but chemotherapy plays
an important role in prolonging disease free and overall sur-
vival of patients with CRC.3
The Kristen Rat Sarcoma (KRAS) gene encodes a signal
transduction protein, which in its active state forms a complex
with a guanosine triphosphate (GTP) group. This complex is
inactivated by the hydrolysis of GTP to guanosinediphosphate
(GDP). The frequency of mutations in the KRAS gene in spo-
radic CRC is 30–50%.4,5 It can be as high as 90% in pancreatic
cancer mostly in codon 12.6 The most common mutations
found in CRC are in exon 2 and to a lesser magnitude in exon
3.5 If KRAS is mutated, the resulting complex is less sensitive
to hydrolysis, remaining in a constitutively active state, leading
to cell proliferation by a variety of signaling pathways, includ-
ing the mitogen-activated protein kinases (MAPKs) path-
way.6,7 A high frequency of mutations in this gene in benign
lesions suggests that, although providing a selective growth
advantage to cells, it is not sufﬁcient by itself to trigger tumor
genesis. The accumulation of mutations in this gene and oth-
ers, including the APC gene, will presumably give a selective
advantage to the mutated cells, resulting in their clonal prolif-
eration.8 When KRAS is activated, it induces theMAPK signal
transduction cascade, transferring signals from the cell mem-
brane to the nucleus. The proteins encoded by the RAS gene
activate RAF family proteins of transcription factors. The acti-
vation of these transcription factors leads to the expression of
proteins that control the cell cycle.9–11
The addition of biologic agents that target speciﬁc signaling
pathways involved in colon tumorgenesis signiﬁcantly
improved the response rate (RR) and overall survival (OS).
However, 40–50% of mCRC patients neither show clinical
beneﬁt nor suffer from severe toxicity. Therefore, the quest
for molecular markers that could predict the response to bio-
logical agent and improve clinical beneﬁt began. The KRAS
gene was one of the ﬁrst studied due to its involvement in
CRC carcinogenesis. The ﬁrst retrospective studies that evalu-
ated KRAS mutation status in patients treated with cetuximab
or panitumumab revealed a signiﬁcant association of favorable
response in patients with KRASWT, with RRs of 17–48%, but
no response in patients with KRAS mutation.12–18 The CRYS-
TAL and the OPUS clinical trials were the ﬁrst to prospec-
tively evaluate KRAS mutational status and clinical response
to cetuximab.19,20 CRYSTAL trial patients were treated withFOLFIRI alone or FOLFIRI + Cetuximab, whereas OPUS
trial patients were treated with FOLFOX alone or FOL-
FOX+ Cetuximab. Substantial association was observed
between response to Cetuximab treatment and KRAS WT sta-
tus in both studies, with no beneﬁt seen in patients who had a
KRAS mutation. This association was observed both in RR
and progression-free survival. With this evidence, the Ameri-
can Society of Clinical Oncology recommended KRAS muta-
tion testing in patients who are candidates of anti-EGFR
therapy.21
In Venezuela Estrada et al.22 reported mutations in codons
12 and 13 of the KRAS gene in 23.33% of patients. Of these,
28.57% were in codon 12, 57.14% were in codon 13 and
14.29% in both codons. They were more frequent in tumors
located in the left hemicolon and most of them were well dif-
ferentiated adenocarcinomas (58.70%) and mucinous
(28.57%). The identiﬁed mutations were more frequent in
Dukes C2 stage of CRC.
In Netherland, 37% (271/737) of CRC patients had KRAS
mutation at exon 1. The predominant mutations are G > A
transitions and G > T transversions, and codons 12 and 13
are the most frequently affected codons. Patients with a rectal
tumor were found to have the highest frequency of G > T
transversions as compared with patients with a colon or recto-
sigmoid tumor. This difference appeared to be conﬁned to
women with a rectal tumor harboring G> T transversions.
The equal distribution of KRAS mutations among cases with
or without a family history of colorectal cancer debates against
an important role for this mutation in hereditary colorectal
cancer, and could imply that KRAS mutations involving envi-
ronmental mechanism rather than familial.23
In USA, Minoo et al.24 suggested that colorectal cancer
(CRC) should be viewed as heterogeneous disease, in his study
399 patients were evaluated for clinicopathological and
molecular proﬁle including KRAS, BRAF and MSI status.
Proximal tumors showed signiﬁcantly larger size, higher T-
stage, more mucinous differentiation and high grade. There
were high frequency of BRAF mutations andMSI-high pheno-
type in proximal colon cancers. Data were supporting the con-
cept that proximal and distal CRCs are distinct pathological
entities.
An Indian study25 was done to ﬁnd out KRAS gene muta-
tion in CRC patients among the Kashmiri population. In a
sample of 53 patients 12 had KRAS mutations (22.64%).
KRAS mutation was signiﬁcantly associated with advanced
Duke stage (P< 0.05) and positive lymph node (P< 0.05).
Moreover codon 12 KRAS mutations were associated with
mucinous histotype (P< 0.05).
The aim of the current study is to evaluate the prevalence of
KRAS mutation among the Saudi population treated at the
King Fahad Medical City and try to correlate it with other
clinicopathological factors and response to treatment.
Table 1 Baseline characteristics of patients with colorectal
cancer.
Characteristics Value
N %
Total number of patients 83
Age, median (range) 55 (Range: 26–90 years)
20–40 years 15 18
40–60 years 39 46.9
60–80 years 27 32.5
80–90 years 2 2.4
Gender (male/female) 48/35 57.8/42.2
Histologic Grade
1 7 8.4
2 68 82
3 8 9.6
Histologic Type
Invasive adenocarcinoma 69 83.1
Mucinous adenocarcinoma 13 15.6
Primary tumor site
(Colon/rectum)
63/20 76/24
Primary stage
(AJCC/Duke’s classiﬁcation)
Stage I/Duke’s A 3 3.6
Stage II A/Duke’s B 5 6
Stage II B/Duke’s B 3 4.8
Stage III A/Duke’s C 6 7.2
Stage III B/Duke’s C 7 8.4
Stage III C/Duke’s C 2 2.4
Stage IV A/Duke’s D 25 30.1
Stage IV B/Duke’s D 32 38.5
No. patients with KRAS mutation 35 42.2
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2.1. Study population
The study was approved by the institutional Review Board. A
total of 83 samples of referred colorectal cancer tumor tissue
specimens were utilized in this study. Medical records and
medical database of these patients were investigated and rele-
vant data were retrieved for analysis. The data retrieved
include: age, date of diagnosis, gender, stage of disease as
determined by the American Joint Committee on Cancer
(AJCC), metastatic sites and response to treatment.
2.2. Tissue samples and mutation analyses
Tumor tissue embedded in parafﬁn was collected and sent to
Biomnis lab in Lyon, France (LCD-Array)26 for the detection
of mutations within codons 12 and 13 of Kras exon 2. The
mutations tested were: p.G12S, p.G12R, p.G12C, p.G12D,
p.G12A, p.G12V, p.G13D, p.G13R. The KRAS LCD-array
kit for the detection of mutations in codon 12 and 13 of the
human KRAS gene is based on the ampliﬁcation of a short
PCR fragment spanning both codons, and the subsequent
identiﬁcation of point mutations in codon 12 and 13 by ampli-
con hybridization to immobilize the capture probes. Biotin
labeling of the generated 170 bp PCR fragment occurs during
PCR ampliﬁcation. Following a short hybridization to WT
and mutation speciﬁc capture probes immobilized on the sur-
face of the LCD-Array, bound PCR fragments are visualized
using the sensitive streptavidin-enzyme-substrate cascade. To
detect even small amounts of mutated KRAS sequences within
an excess amount of WT background, ampliﬁcation will be
carried out in the presence of the KRAS WT suppressor com-
pound (KRAS WSC). This molecule preferentially suppresses
WT sequence ampliﬁcation and therefore allows sequence-spe-
ciﬁc detection of the smallest amounts of KRAS mutations in
codon 12 and 13.
2.3. Evaluation of response to chemotherapy
Tumor response was evaluated by CT after 12 and 24 weeks of
ﬁrst-line chemotherapy with 5FU/leucovorin or 5FU/leucovo-
rin/Oxaliplain or 5FU/leucovorin/Irinotecan in mCRC.
Response evaluation criteria in solid tumors (RECIST) were
used to classify tumor response in complete response CR, par-
tial response PR, stable disease SD and progressive disease
(PD).27 The PFS was calculated from the commencement of
chemotherapy to either progression of disease, death from
any cause or last radiological assessment.
2.4. Statistical analysis
The overall frequency of KRAS mutations as well as the type
of mutation and affected codon will be computed for all cases
with respect to age at diagnosis, gender, tumor anatomical
sub-localization, AJCC stage and histological differentiation.
A difference in mean values of age at diagnosis as a continuous
variable was evaluated using the Student’s t-test. Differences in
the categorical variables such as gender, tumor anatomical
sub-localization, AJCC stage and tumor differentiationbetween patients without and with KRAS mutations were eval-
uated for signiﬁcance with the chi-square and Fisher’s Exact
tests. A P-value of 0.05 or less is considered statistically signif-
icant. Multivariate logistic regression model is used to deter-
mine the prognostic value of KRAS mutation after adjusting
baseline variables. Statistical analysis was performed using
the SPSS software.
3. Results
The median age of patients was 55 years (ranging from 26 to
90 years). Majority of the patients were between 40 and
60 years of age (47%). Male to female ratio was 1.3:1. Invasive
adenocarcinoma was the dominant histological type with 83%
and 87% were advanced stage Dukes C and D. (Table 1).
KRAS mutation was observed in 42.2% (35/83) patients with
colorectal cancer (Table 1).
Of all cases investigated 42.2% showed mutations in exon 2
of codon 12 and codon 13 of the KRAS gene. Conversely,
57.8% showed signiﬁcant WT sequence (Fisher’s test;
P< 0.0001). The most common mutations were glycine to
aspartate on codon 12 (p.G12D, 45.7% of all mutated tumors;
16 of 35 (P< 0.0001), glycine to valine on codon 12 (pG12V;
31.4 of mutated tumors; 11 of 35; P< 0.0001), and glycine to
aspartate on codon 13 (p.G13D, 11.4% of mutated tumors; 4
of 35, (P< 0.016). These three types account for 88.5% of all
Table 4 KRAS mutation in mCRC according to metastatic
site.
Metastatic sites Mutated KRAS WT KRAS P Value
N % N %
Liver 5 22.7 17 53.1 0.005
206 T. Bader, A. Ismailmutations (Table 2). Other types of mutations were less
frequent.
Of the studied patients 51.4% and 22.8% of the tumors are
from the left hemicolon and rectum respectively, 82.6% were
moderately differentiated and 85.7% were invasive adenocarci-
noma. Observed mutations are 74.2% in patients with
advanced-stage colorectal cancer (P= 0.006; Table 3). The
frequency of KRAS gene mutations observed in men (23/35;
66%) was higher than that observed in women (12/35; 34%),
but the difference was not signiﬁcant (P= 0.21) probably
due to the small sample size.
Among the KRAS mutation-positive colorectal cancer
patients 32% had isolated lung metastases compared to a sig-
niﬁcantly lower proportion of 3% in WT KRAS (P< 0.005;
Table 4).
We have grouped CR, PR and SD together for the purposes
of analysis. In colorectal cancer with KRAS mutation 68.6%
had CR, PR and SD vs. 81.3% in WT KRAS colorectal cancer.
In the mutated KRAS cohort 31% had disease progression
compared to 19% in WT KRAS (P= 0.182; Table 5).Table 2 Codon distribution of speciﬁc KRAS mutations.
Mutations No. of
patients
P Value*
Gly 12Asp(GGT>GAT)- - - - -p.G12 D 16 <0.0001
Gly 12 Val (GGT>GTT)- - - - -p.G12 V 11 <0.0001
Gly 12Cys (GGT> TGT) - - - - -p.G12 C 3 <0.0001
Gly12 Ser (GGT> AGT)- - - - -p.G12 S 1 <0.0001
Gly 13Asp (GGT> GAC) - - - - -p.G13 D 4 <0.0001
* Signiﬁcant P< 0.05.
Table 3 Relationship between KRAS mutation status and tumor v
Mutated KRAS
N %
Gender
Male 23 65.7
Female 12 34.3
Tumor location
Rectum 8 22.8
Sigmoid 16 45.7
Ascending colon 7 20
Descending colon 2 5.7
Cecum 2 5.7
Histologic grade
Well diﬀerentiated 4 11.4
Moderately diﬀerentiated 29 82.8
Poorly diﬀerentiated 2 5.7
Histological type
Invasive Adenocarcinoma 30 85.7
Mucinous Adenocarcinoma 5 14.2
Others –
Primary tumor stage
Duke A & B 9 25.7
Duke C & D 26 74.2
WT: wild type3.1. Multivariate analysis
The multivariate logistic regression analysis, after adjusting for
baseline variables, showed that the WT colorectal cancer was
associated with a 3-fold increase in its positive response to
ﬁrst-line chemotherapy with an odds ratio 2.83; 95% CI
0.910–8.832 (Table 6).
4. Discussion
It is widely accepted that KRASmutations are among the most
vital transforming genetic change occurring during colorectalariables.
WT KRAS P Value
N %
25 52.1 0.21
23 47.9
12 25 0.32
18 37.5
5 10.4
5 10.4
8 17.6
3 6.2 0.44
39 81.3
6 12.5
39 81.2 0.59
9 18.8
–
2 4.2 0.006
46 95.8
Lung 7 31.8 1 3.1
WT: wild type; mCRC: metastatic colorectal cancer.
Table 5 KRAS mutation status and response to treatment.
Response Mutated KRAS WT KRAS P Value
N % N %
CR/PR/SD 24 68.5 39 81.2 0.182
PD 11 31.5 9 18.8
CR: complete response; PR: partial response; SD: stable disease;
PD: progressive disease; WT KRAS: wild type KRAS.
Table 6 Multivariate analysis of response to treatment in
mutated KRAS colorectal cancer patients.
Odds ratio estimates 95% CI
KRAS 2.836 0.910–8.832
Stage 0.799 0.568–1.069
Age 1.025 0.982–1.070
Histologic grade 0.466 0.119–1.820
CI: conﬁdence interval.
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the board in CRC from western countries limited data are
available in mutation rates and spectrum of CRC from devel-
oping countries like Saudi Arabia. The present ﬁndings sug-
gests a higher incidence of CRC in Saudi Arabia comparable
to previous ﬁndings in Saudi Arabia28,29 among the younger
age group with more aggressive clinical manifestations com-
pared to reports from the Western world.23,24 The KRAS
mutation analyses of colorectal cancer patients revealed a fre-
quency of 42.2% which is higher than the frequency reported
(30% and 23%) by Smith and co-workers4 and Sameer
et al.25, respectively. This goes to emphasize the signiﬁcance
of geographical variation.
The liver and the lung are frequent sites of CRC metastases.
Due to their respective anatomical blood vessel distribution,
lung metastases are more frequent with rectal cancers while
liver metastases are more common with colon cancers. How-
ever, some colon cancer patients can have lung metastases
without evidence of previous liver metastases. This unascer-
tained anatomical pattern of metastasis, observed with increas-
ing frequency due to more precise diagnoses based on highly
effectual CT scans, suggests an unusual biological mechanism
of carcinogenesis in these patients.30,31
A recent report by Yamauchi et al.32 of the anatomical dif-
ference between right and left colon with data from 1400 colo-
rectal cancers from two prospective trials; the frequencies of
molecular markers CIN (chromosomal instability), MSI
(Microsatellite instability), CIMP (CpG island methylator phe-
notype and BRAF. They reported that frequencies of CIMP,
MSI and BRAF mutation increased in a statistically linear
fashion from the rectum to the ascending colon, while the
KRAS mutation was high in ceacal cancer. This supports that
the frequencies of molecular pathological changes in colorectal
cancer evolve gradually through the bowel subsites. In our
study, it looks very difﬁcult to draw a conclusion in this regard
because of the very small sample size. For example, only two
patients in both ceacum and descending colon were reported
as mutant KRAS while ﬁve and eight patients were wild type
(5.7%, 10.4% and 17.6%, respectively) while the ascending
colon has mutant KRAS in seven patients and wild type in only
ﬁve patients (20% and 10.4%, respectively) again the tumor
location was not of signiﬁcant value (P= 0.32) for the KRAS
mutation (Table 3).
It was quite consistent in our study that the prevalence of
mutation is highly signiﬁcant with the tumor stage 25.7% for
stage Duke A and B compared with 74.2% for stage Duke C
and D (P= 0.006).
In the present study among the KRAS mutation positive
colorectal cancer patients the incidence of isolated lung metas-
tases was much higher compared to WT KRAS irrespective of
anatomical location of cancer. This ﬁnding suggests thatEGFR pathway activation may allow colonic tumor cells to
metastasize in the lung parenchyma avoiding an initial step
of liver metastasis. This holds clinical signiﬁcance in identify-
ing patients with a greater propensity toward lung metastasis
based on KRAS mutation. These patients need thorough
workup speciﬁcally chest imaging which is not always included
in the work-up for CRC. Critical analyses of lung nodules even
borderline for malignancy is needed based on current ﬁndings.
The fact that in present and previous31 ﬁndings the liver was
bypassed in favor of lungs supports the previous statement
for more vigilant work-up inclusive of chest imaging.
Our study is supported by an elegant work of Tie et al.33;
they reviewed three sets of patients population: A total of
148 patients with 161 resected colorectal cancer metastases
were identiﬁed (cohort A), the second set was an independent
clinic-based cohort of 604 patients with primary colon cancers
was identiﬁed (cohort B) with stage I to IV. The third set was
retrieved from 859 stage II and III patients participating in the
VICTOR clinical trial (cohort C). All patients had undergone
curative-intent surgery, and none had shown evidence of dis-
tant metastases at the time of surgery. They reported preva-
lence of 19 oncogenes among this large patient population
including BRAF, KRAS, NRAS, and PIK3CA mutation.
Their data showed high concordance between the muta-
tions in both primary and metastatic site for KRAS, BRAF,
NRAS and PIK3CA.
KRAS mutation frequency was similar in liver metastases
(32.3%, P= 0.784), but signiﬁcantly higher in lung (62.0%)
and brain (56.5%) metastases (P< 0.001 and P= 0.004,
respectively). This conﬁrms that KRAS mutation in the pri-
mary tumor may be associated with an increased risk of
relapse in the lung or brain, but may not modify the risk of
relapse in the liver.
Taken together our ﬁndings and Tie et al.33 results support
more comprehensive assessment of chest imaging prior to rad-
ical treatment and in the follow up especially during the ﬁrst
three years after radical surgery.
No appreciable difference could be ascertained histopatho-
logically between KRAS mutated and WT CRC (P
value = 0.59). On the contrary, an Indian study of 53 patients
with CRC showed codon 12 KRAS mutation signiﬁcantly
associated with mucinous histotype.25
The KRAS mutation state of the tumor has been proposed
as a strong marker of response to chemotherapy in mCRC.18
With the advent of KRAS mutation as a negative predictive
marker in colorectal cancer the EGFR monoclonal antibodies
have been rapidly incorporated in our clinical practice for
KRAS WT type colorectal cancer.15–19 Several questions
remain unanswered, large data from MRC COIN (continuous
chemotherapy plus cituximab, or intermittent chemotherapy
with standard continuous palliative combination chemother-
apy with Oxaliplatin and a ﬂuoropyrimidine in ﬁrst-line treat-
ment of metastatic colorectal cancer) trial showed no
progression free survival advantage on addition of cituximab.31
A recent large study in Korean population by Kim et al.35
also reported high prevelance of lung metastasis in patients
with mutated K-ras tumors; They found mutations in 75 cases
out of 143 (in both primary and metastatic sites) with 52%
being mutated tumors, and lung metastasis was found in
42% of the mutated tumors while only 22% of those tumors
developed liver metastasis (P= 0.003). Again patients with
wild type tumors had more prevalence of liver metastasis than
208 T. Bader, A. Ismailthose with mutated tumors (70% vs. 22% P= 0.002). More
interestingly they also found higher incidence of discordance
between primary tumors and metastatic site in patients who
developed lung metastasis (32.4% compared with 12.3%
P= 0.005).
The present study showed the existence of an association
between KRAS WT and its positive response to conventional
5-FU chemotherapy irrespective of the supplementation of
EGFR monoclonal antibodies.
The higher incidence of KRAS mutation of colorectal can-
cer patients in the study population is intriguing. A plausible
reason is the small sample size which is not representative of
the entire population. A larger study may enable a more accu-
rate inference.
5. Conclusion
The frequency of KRAS mutations appears higher in the Saudi
population. KRAS mutated colorectal cancer patients had a
higher propensity for lung metastases bypassing liver metasta-
ses indicating the need for more extensive chest imaging for
effective staging.
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